Awakening guardian angels: drugging the p53 pathway

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113

hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase

Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,690

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12

McClurg, U. L., Chit, N. C. T. H., Azizyan, M., Edwards, J., Nabbi, A., Riabowol, K. T., Nakjang, S., McCracken, S. R., & Robson, C. N. (2018) · Oncogene · doi:10.1038/s41388-018-0283-3 · Cited by 46

One-Dimensional Sliding of p53 Along DNA Is Accelerated in the Presence of Ca2+ or Mg2+ at Millimolar Concentrations

Murata, A., Ito, Y., Kashima, R., Kanbayashi, S., Nanatani, K., Igarashi, C., Okumura, M., Inaba, K., Tokino, T., Takahashi, S., et al. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.06.016 · Cited by 44

Ubiquitin-independent proteasomal degradation during oncogenic viral infections

Hwang, J., Winkler, L. L., & Kalejta, R. F. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.05.005 · Cited by 46

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL

Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 44

From protein interaction networks to novel therapeutic strategies

Jaeger, S., & Aloy, P. (2012) · IUBMB Life · doi:10.1002/iub.1040 · Cited by 44

The impact of post-transcriptional regulation in the p53 network

Freeman, J. A., & Espinosa, J. M. (2012) · Briefings in Functional Genomics · doi:10.1093/bfgp/els058 · Cited by 46

HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches

Tornesello, M. L., Perri, F., Buonaguro, L., Ionna, F., Buonaguro, L., & Caponigro, F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.003 · Cited by 47

Markov state models and NMR uncover an overlooked allosteric loop in p53

de Barros, E. P., Demir, Ö., Soto, J., Cocco, M. J., & Amaro, R. E. (2020) · Chemical Science · doi:10.1039/d0sc05053a · Cited by 45

Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells

Sonnemann, J., Palani, C. D., Wittig, S., Becker, S., Eichhorn, F., Voigt, A., & Beck, J. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.015 · Cited by 43

Transient Transfection of a Wild-Type p53 Gene Triggers Resveratrol-Induced Apoptosis in Cancer Cells

da Costa, D. C. F., Casanova, F. A., Quarti, J., Malheiros, M. S., Sanches, D., Santos, P. S., Fialho, E., & Silva, J. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048746 · Cited by 43

MicroRNAs: New Players in Multiple Myeloma

Pichiorri, F., Luca, L. D., & Aqeilan, R. I. (2011) · Frontiers in Genetics · doi:10.3389/fgene.2011.00022 · Cited by 43

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance

Chen, L., & Tweddle, D. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00173 · Cited by 43

Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

Azmi, A. S., Philip, P. A., Aboukameel, A., Wang, Z., Banerjee, S., Zafar, S. F., Goustin, A. S., Almhanna, K., Yang, D., Sarkar, F. H., et al. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791190229 · Cited by 42

Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design

Tan, Y. S., Reeks, J., Brown, C. J., Thean, D., Ferrer‐Gago, F. J., Yuen, T. Y., Goh, E. T. L., Lee, X. C., Jennings, C., Joseph, T. L., et al. (2016) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.6b01525 · Cited by 42

Melatonin: Regulation of Biomolecular Condensates in Neurodegenerative Disorders

Loh, D., & Reiter, R. J. (2021) · Antioxidants · doi:10.3390/antiox10091483 · Cited by 45

PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b

Luo, S., Wang, J., Ma, Y., Yao, Z., & Pan, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.023 · Cited by 43

Covalent Small Molecule Inhibitors of Ca2+-Bound S100B

Cavalier, M. C., Pierce, A. D., Wilder, P. T., Alasady, M. J., Hartman, K. G., Neau, D. B., Foley, T. L., Jadhav, A., Maloney, D. J., Simeonov, A. M., et al. (2014) · Biochemistry · doi:10.1021/bi5005552 · Cited by 42

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Li, X., Gohain, N., Chen, S., Li, Y., Zhao, X., Li, B., Tolbert, W. D., He, W., Pazgier, M., Hu, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.010 · Cited by 46

Native and Engineered Cyclic Disulfide-Rich Peptides as Drug Leads

Tyler, T. J., Durek, T., & Craik, D. J. (2023) · Molecules · doi:10.3390/molecules28073189 · Cited by 42

p53 and Ceramide as Collaborators in the Stress Response

Hage‐Sleiman, R., Esmerian, M. O., Kobeissy, H., & Dbaibo, G. S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14034982 · Cited by 42

Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity

VOON, Y.-L., Ahmad, M., Wong, P., Husaini, R., Ng, W., Leong, C., Lane, D. P., & Khoo, A. S. B. (2015) · Oncology Reports · doi:10.3892/or.2015.4177 · Cited by 42

Current status of mathematical modeling of cancer – From the viewpoint of cancer hallmarks

Magi, S., Iwamoto, K., & Okada, M. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.02.008 · Cited by 43

Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics

He, W., Yan, J., Li, Y., Yan, S., Wang, S., Hou, P., & Lu, W. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.041 · Cited by 42

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers

Wu, C., Pan, Y., Yeh, C., & Lunec, J. (2020) · Biomolecules · doi:10.3390/biom10111474 · Cited by 44

Inhibition of tumor angiogenesis and growth by nanoparticle-mediated p53 gene therapy in mice

Prabha, S., Sharma, B., & Labhasetwar, V. D. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.26 · Cited by 42

From cultivation to cancer: formation of N -nitrosamines and other carcinogens in smokeless tobacco and their mutagenic implications

Stanfill, S. B., Hecht, S. S., Joerger, A. C., González, P. J., Maia, L. B., Rivas, M. G., Moura, J. J. G., Gupta, A., Brun, N. E. L., Crack, J. C., et al. (2023) · Critical Reviews in Toxicology · doi:10.1080/10408444.2023.2264327 · Cited by 45

Linear Aliphatic Dialkynes as Alternative Linkers for Double‐Click Stapling of p53‐Derived Peptides

Lau, Y. H., de Andrade, P., McKenzie, G. J., Venkitaraman, A. R., & Spring, D. R. (2014) · ChemBioChem · doi:10.1002/cbic.201402374 · Cited by 43

miRNA interventions serve as ‘magic bullets’ in the reversal of glioblastoma hallmarks

Chen, L., & Kang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.5926 · Cited by 40

Competitive ubiquitination activates the tumor suppressor p53

Li, X., Guo, M., Cai, L., Du, T., Liu, Y., Ding, H., Wang, H., Zhang, J., Chen, X., & Yan, C. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0463-x · Cited by 42

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Tovar, C., Higgins, B., Kolinsky, K. D., Xia, M., Packman, K. E., Heimbrook, D. C., & Vassilev, L. T. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-49 · Cited by 41

MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy

Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40

TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates

Santini, V., Stahl, M. F., & Sallman, D. A. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432650 · Cited by 52

Assessing the Efficacy of Mdm2/Mdm4-Inhibiting Stapled Peptides Using Cellular Thermal Shift Assays

Tan, B. X., Brown, C. J., Ferrer, F. J., Yuen, T. Y., Quah, S. T., Chan, B. H., Jansson, A. E., Teo, H., Nordlund, P., & Lane, D. P. (2015) · Scientific Reports · doi:10.1038/srep12116 · Cited by 40

The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer

Roh, J.-L., Ko, J. H., Moon, S. J., Ryu, C. H., Choi, J. Y., & Koch, W. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.020 · Cited by 40

Triple-negative breast cancer

Hirshfield, K. M., & Ganesan, S. (2013) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000038 · Cited by 40

A Synthetic Interaction Screen Identifies Factors Selectively Required for Proliferation and TERT Transcription in p53-Deficient Human Cancer Cells

Xie, L., Gazin, C., Park, S. M., Zhu, L. J., Debily, M.-A., Kittler, E. L. W., Zapp, M. L., Lapointe, D. S., Gobeil, S., Virbasius, C.-M. A., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003151 · Cited by 41

Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein

Dong, C., Zhao, B., Long, F., Liu, Y., Liu, Z., Li, S., Yang, X., Sun, D., Wang, H., Liu, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7091 · Cited by 40

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma

Wu, C., Koay, T. S., Esfandiari, A., Ho, Y.-H., Lovat, P. E., & Lunec, J. (2018) · Cancers · doi:10.3390/cancers11010003 · Cited by 40

Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate

Zhao, M., Yao, P., Mao, Y., Wu, J., Wang, W., Geng, C., Cheng, J., Du, W., & Jiang, P. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00532-w · Cited by 40

Evolutionarily conserved transcription factors as regulators of longevity and targets for geroprotection

Fischer, F., Grigolon, G., Benner, C., & Ristow, M. (2022) · Physiological Reviews · doi:10.1152/physrev.00017.2021 · Cited by 42

Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy

Yi, J., Tavana, O., Li, H., Wang, D., Baer, R. J., & Gu, W. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37617-3 · Cited by 45

Transcription factors and chromatin proteins as therapeutic targets in cancer

Johnston, S. J., & Carroll, J. S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.02.002 · Cited by 41

Restoration of DNA‐binding and growth‐suppressive activity of mutant forms of p53 via a PCAF‐mediated acetylation pathway

Perez, R. E., Knights, C. D., Sahu, G., Catania, J., Kolukula, V. K., Stoler, D. L., Graessmann, A., Ogryzko, V. V., Pishvaian, M. J., Albanese, C., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22285 · Cited by 40

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia

Kaindl, U., Morak, M., Portsmouth, C., Mecklenbräuker, A., Kauer, M., Zeginigg, M., Attarbaschi, A., Haas, O. A., & Panzer‐Grümayer, R. (2013) · Leukemia · doi:10.1038/leu.2013.345 · Cited by 39

PPARγ ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells

Kim, S., Lee, J.-J., & Heo, D. S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.052 · Cited by 39

USP22 Promotes NSCLC Tumorigenesis via MDMX Up-Regulation and Subsequent p53 Inhibition

Ding, F., Bao, C., Tian, Y., Xiao, H., Wang, M., Xie, X., Hu, F., & Mei, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010307 · Cited by 38

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy

Louwen, F., & Yuan, J. (2013) · Oncotarget · doi:10.18632/oncotarget.1096 · Cited by 38

A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX

Henry, R. E., Andrysík, Z., París, R., Galbraith, M. D., & Espinosa, J. M. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.498 · Cited by 40

Molecular events in the pathogenesis of vulvar squamous cell carcinoma

Xing, D., & Fadare, O. (2020) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2020.09.010 · Cited by 38

Pharmacological Activation of p53 in Cancer Cells

Athar, M., Elmets, C. A., & Kopelovich, L. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222595 · Cited by 40

Identification of HEXIM1 as a Positive Regulator of p53

Lew, Q. J., Chia, Y. L., Chu, K. L., Lam, Y. T., Gurumurthy, M., Xu, S., Lam, K., Cheong, N., & Chao, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.374157 · Cited by 37

p53 activates G1 checkpoint following DNA damage by doxorubicin during transient mitotic arrest

Hyun, S., & Jang, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.3103 · Cited by 38

Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53–MDM2 interaction

Li, C., Zhan, C., Zhao, L., Chen, X., Lu, W., & Lu, W. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.039 · Cited by 37

Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A

Gupta, R., Dong, Y., Solomon, P. D., Wettersten, H. I., Cheng, C. J., Min, J., Henson, J. D., Dogra, S. K., Hwang, S. H., Hammock, B. D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411370111 · Cited by 36

On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study

ElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 37

Prognostic significance of KAI1/CD82 in human melanoma and its role in cell migration and invasion through the regulation of ING4

Tang, Y., Cheng, Y., Martinka, M., Ong, C. J., & Li, G. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt346 · Cited by 37

Preferential killing of p53-deficient cancer cells by reversine

Jèmaà, M., Galluzzi, L., Kepp, O., Boilève, A., Lissa, D., Senovilla, L., Harper, F., Pierron, G., Berardinelli, F., Antoccia, A., et al. (2012) · Cell Cycle · doi:10.4161/cc.20621 · Cited by 38

Multifaceted Roles of TRIM Proteins in Colorectal Carcinoma

Eberhardt, W., Haeussler, K., Nasrullah, U., & Pfeilschifter, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207532 · Cited by 39

Modulation of Butyrate Anticancer Activity by Solid Lipid Nanoparticle Delivery: An in Vitro Investigation on Human Breast Cancer and Leukemia Cell Lines

Foglietta, F., Serpe, L., Canaparo, R., Vivenza, N., Riccio, G., Imbalzano, E., Gasco, P., & Zara, G. P. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3xp4r · Cited by 37

NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer*

Lund, R. R., Leth‐Larsen, R., Caterino, T. D., Terp, M. G., Nissen, J., Lænkholm, A., Jensen, O. N., & Ditzel, H. J. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.050385 · Cited by 36

Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53

Soong, R.-S., Trieu, J., Lee, S. Y., He, L., Tsai, Y.-C., Wu, T. ‐., & Hung, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056912 · Cited by 36

Revisiting p53 for cancer-specific chemo- and radiotherapy

Beckta, J. M., Ahmad, S. F., Yang, H., & Valerie, K. C. (2014) · Cell Cycle · doi:10.4161/cc.28108 · Cited by 36

Ligand Binding Mode Prediction by Docking: Mdm2/Mdmx Inhibitors as a Case Study

Bharatham, N., Bharatham, K., Shelat, A. A., & Bashford, D. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci4004656 · Cited by 37

The Fluorescent Two-Hybrid Assay to Screen for Protein–Protein Interaction Inhibitors in Live Cells: Targeting the Interaction of p53 with Mdm2 and Mdm4

Yurlova, L., Derks, M., Buchfellner, A., Hickson, I., Janssen, M., Morrison, D., Stansfield, I., Brown, C. J., Ghadessy, F. J., Lane, D. P., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057113518067 · Cited by 35

A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction

Surmiak, E., Twarda‐Clapa, A., Żak, K. M., Musielak, B., Tomala, M. D., Kubica, K., Grudnik, P., Madej, M., Jabłoński, M., Potempa, J., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00596 · Cited by 36

Characterization of facilitated diffusion of tumor suppressor p53 along DNA using single-molecule fluorescence imaging

Kamagata, K., Murata, A., Itoh, Y., & Takahashi, S. (2017) · Journal of Photochemistry and Photobiology C Photochemistry Reviews · doi:10.1016/j.jphotochemrev.2017.01.004 · Cited by 36

Multi-region and single-cell sequencing reveal variable genomic heterogeneity in rectal cancer

Liu, M., Liu, Y., Di, J., Su, Z., Yang, H., Jiang, B., Wang, Z., Zhuang, M., Bai, F., & Su, X. (2017) · BMC Cancer · doi:10.1186/s12885-017-3777-4 · Cited by 36

A DDX31/Mutant–p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer

Daizumoto, K., Yoshimaru, T., Matsushita, Y., Fukawa, T., Uehara, H., Ono, M., Komatsu, M., Kanayama, H., & Katagiri, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2528 · Cited by 34

MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma

Fan, X., Wang, Y., Song, J., Wu, H., Yang, M., Lu, L., Weng, X., Liu, L., & Nie, G. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1638677 · Cited by 36

The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis

Kashyap, A., Zimmerman, T., Ergül, N., Bosserhoff, A., Hartman, U., Alla, V., Bataille, F., Galle, P. R., Strand, S., & Strand, D. (2012) · Oncogene · doi:10.1038/onc.2012.162 · Cited by 37

Activation of p53 Facilitates the Target Search in DNA by Enhancing the Target Recognition Probability

Itoh, Y., Murata, A., Sakamoto, S., Nanatani, K., Wada, T., Takahashi, S., & Kamagata, K. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.06.001 · Cited by 36

Development of cell‐penetrating peptide‐based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions

Philippe, G. J.-B., Huang, Y., Cheneval, O., Lawrence, N., Zhang, Z., Fairlie, D. P., Craik, D. J., de Araujo, A. D., & Henriques, S. T. (2016) · Biopolymers · doi:10.1002/bip.22893 · Cited by 35

Mechanism of initiation of aggregation of p53 revealed by Φ-value analysis

Wang, G., & Fersht, A. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500243112 · Cited by 35

Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73

Venkatanarayan, A., Raulji, P., Norton, W., & Flores, E. R. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1121333 · Cited by 35

Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells

Safa, M., Tavasoli, B., Shabestari, R. M., Kiani, F., Kashiri, M., Ebrahimi, S., & Kazemi, A. (2015) · Tumor Biology · doi:10.1007/s13277-014-3035-1 · Cited by 34

Chemical Variations on the p53 Reactivation Theme

Ribeiro, C. J. A., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2016) · Pharmaceuticals · doi:10.3390/ph9020025 · Cited by 37

Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction

Surmiak, E., Neochoritis, C. G., Musielak, B., Twarda‐Clapa, A., Kurpiewska, K., Dubin, G., Camacho, C. J., Holak, T. A., & Dömling, A. S. S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.029 · Cited by 34

Coumarin-chalcone hybrid instigates DNA damage by minor groove binding and stabilizes p53 through post translational modifications

Ashraf, R., Hamidullah, Hasanain, M., Pandey, P., Maheshwari, M., Singh, L., Siddiqui, M. Q., Konwar, R., Sashidhara, K. V., & Sarkar, J. (2017) · Scientific Reports · doi:10.1038/srep45287 · Cited by 33

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Hata, A. N., Rowley, S. C., Archibald, H. L., Gomez‐Caraballo, M., Siddiqui, F. M., Ji, F., Jung, J., Light, M. E., Lee, J. S., Debüssche, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.258 · Cited by 35

Effect of StarD13 on colorectal cancer proliferation, motility and invasion

Nasrallah, A., Saykali, B., Dimassi, S. A., KHOURY, N., Hanna, S. J., & El‐Sibai, M. (2013) · Oncology Reports · doi:10.3892/or.2013.2861 · Cited by 34

Cellular Stress and p53-Associated Apoptosis by Juniperus communis L. Berry Extract Treatment in the Human SH-SY5Y Neuroblastoma Cells

Lantto, T. A., Laakso, I., Dorman, H. J. D., Mauriala, T., Hiltunen, R., Kõks, S., & Raasmaja, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071113 · Cited by 34

Wild-Type p53 Attenuates Cancer Cell Motility by Inducing Growth Differentiation Factor-15 Expression

Cheng, J., Chang, H., & Leung, P. C. K. (2011) · Endocrinology · doi:10.1210/en.2011-0059 · Cited by 34

Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere

Wilcken, R., Zimmermann, M. O., Bauer, M. R., Rutherford, T. J., Fersht, A. R., Joerger, A. C., & Boeckler, F. M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00515 · Cited by 33

DNA repair pathways and their roles in drug resistance for lung adenocarcinoma

Kara, A., Özgür, A., Nalbantoğlu, S., & Karadağ, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06314-z · Cited by 35

HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications.

Markowski, D. N., Helmke, B. M., Belge, G., Nimzyk, R., Bartnitzke, S., Deichert, U., & Bullerdiek, J. (2011) · PubMed · Cited by 33

p53 promotes cellular survival in a context-dependent manner by directly inducing the expression of haeme-oxygenase-1

Nam, S. Y., & Sabapathy, K. (2011) · Oncogene · doi:10.1038/onc.2011.150 · Cited by 33

mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction

Shiheido, H., Takashima, H., Doi, N., & Yanagawa, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017898 · Cited by 33

The relevance of protein-protein interactions for p53 function: the CPE contribution

Fernández-Fernández, M. R., & Sot, B. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq074 · Cited by 33

Ser392 phosphorylation modulated a switch between p53 and transcriptional condensates

Dai, Z., Li, G., Chen, Q., & Yang, X. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194827 · Cited by 32

Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy

Yamaguchi, F., Kugawa, S., Tateno, H., Kokubu, F., & Fukuchi, K. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.014 · Cited by 33

The Application of Ligand-Mapping Molecular Dynamics Simulations to the Rational Design of Peptidic Modulators of Protein–Protein Interactions

Tan, Y. S., Spring, D. R., Abell, C., & Verma, C. S. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/ct5010577 · Cited by 33

Vitamin�D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model

Maj, E., Filip‐Psurska, B., Milczarek, M., Psurski, M., Kutner, A., & Wietrzyk, J. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4228 · Cited by 32

Familial predisposition to adrenocortical tumors: Clinical and biological features and management strategies

Ribeiro, R. C., Pinto, E. M., & Zambetti, G. P. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.03.002 · Cited by 32

Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting

Tan, Y. S., Mhoumadi, Y., & Verma, C. S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz009 · Cited by 34

The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors

Dickinson, E. R., Jurneczko, E., Nicholson, J., Hupp, T. R., Zawacka‐Pankau, J., Selivanova, G., & Barran, P. E. (2015) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00039 · Cited by 31

DEN+2-AAF-induced multistep hepatotumorigenesis in Wistar rats: supportive evidence and insights

Malik, S., Bhatnagar, S., Chaudhary, N., Katare, D. P., & Jain, S. K. (2012) · PROTOPLASMA · doi:10.1007/s00709-012-0392-8 · Cited by 31

Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy

Sharma, B., Peetla, C., Adjei, I. M., & Labhasetwar, V. D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.011 · Cited by 31

1,4,5-Trisubstituted Imidazole-Based p53–MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers

Twarda‐Clapa, A., Krzanik, S., Kubica, K., Guzik, K., Łabuzek, B., Neochoritis, C. G., Khoury, K., Kowalska, K., Czub, M., Dubin, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00104 · Cited by 31

Toolbox of Diverse Linkers for Navigating the Cellular Efficacy Landscape of Stapled Peptides

Wu, Y., Kaur, A., Fowler, E., Wiedmann, M. M., Young, R., Galloway, W. R. J. D., Olsen, L. B., Sore, H. F., Chattopadhyay, A., Kwan, T. T.-L., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00063 · Cited by 34

Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein–Protein Interactions

Shi, Y., Sang, P., Lu, J., Higbee, P. S., Chen, L., Yang, L., Odom, T., Daughdrill, G. W., Chen, J., & Cai, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01638 · Cited by 32

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 742

Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 68

ORIGINAL PAPER Small molecule compounds targeting the p53 pathway: are we finally making progress?

Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014)

The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 675

Translational approaches targeting the p53 pathway for anti‐cancer therapy

Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77